Recently, a new-generation AR antagonist, proxalutamide, independently developed by Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") receives initiation funding for special project of significant novel drugs development in "13th Five-Year plan". On November 30, a contract on National major special scientific and technological project was officially signed in Beijing. The project's pre-clinical research received special funding for major novel drugs innovation in national “12th Five-Year Plan” in 2011. Now, its clinical research has been successfully included in the special project of major novel drugs development in“13th Five-Year Plan”, which means the pre-clinical and clinical stages of proxalutamide have been both recognized at the national level.

Established in 2009, Suzhou Kintor has been making continuous breakthroughs in the development of new anti-cancer drugs under the leadership of Dr. Youzhi Tong and Dr. Chuangxing Guo. Due to this project, Suzhou Kintor  received funding for special project of Significant New Drugs development in National 12th Five-Year Plan, Jiangsu Province Scien and Technology Support Program (Social Development) and Suzhou Science and Technology Program in 2011, and won “Second Prize of Jiangsu Provincial 3rd Pharmaceutical Science and Technology Progress Award” in 2016. Now, it has opened the door to special project of significant novel drugs development in "13th Five-Year Plan". It is reported that Suzhou Kintor  is also one of the few companies in BioBay of Suzhou Industrial Park that has been included in the special project of major novel drugs development in "13th Five-Year Plan" as the project leader unit to receive funding.

Suzhou Kintor has opened up a blue ocean in the fields of prostate cancer and breast cancer. Proxalutamide is a class 1.1 innovative drug used to treat prostate cancer and advanced breast cancer, which has biological effect of inducing down-regulated AR expression on the basis of more effective inhibition of AR, thus an AR antagonist with "dual action mechanism". Proxalutamide clinical trials are concurrently undertaken in China and the United States. Chinese clinical trials have entered Phase III. Clinical data show that proxalutamide has good safety and tolerability. Considering that AR overexpression and mutation are the main mechanism of drug resistance in prostate cancer cells against abiraterone/enzalutamide treatment, while proxalutamide can overcome the resistance of prostate cancer cells to these drugs by down-regulating the expression of AR genes, it is expected to become a more effective and safe new-generation AR antagonist used to treat castration-resistant prostate cancer, which will enjoy a broad market prospect once approved for marketing. Suzhou Kintor will "stay true to the mission", uphold the concept of focusing on druggability and early marketing of innovative drugs, keep concentrated, steady attitude without arrogance and impetuosity. National support is the motivation, and patient satisfaction is the goal. The “12th Five-Year Plan” has laid the foundation, while the “13th Five-Year Plan” will help Suzhou Kintor achieve more steady development.